Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?

Hum Exp Toxicol. 2000 Apr;19(4):205-7. doi: 10.1191/096032700678815855.
No abstract available

MeSH terms

  • Adjuvants, Immunologic / adverse effects*
  • Adjuvants, Immunologic / toxicity*
  • Biopharmaceutics*
  • Drug Evaluation, Preclinical

Substances

  • Adjuvants, Immunologic